Recent investigations of Nogo-A, a well characterized protein inhibitor of neurite outgrowth in the brain, have revealed additional functions including a role in neuropsychiatric disorders such as schizophrenia. Here we examined Nogo-A functions in mouse CA3 hippocampal circuitry. Patch clamp recordings showed that the absence of Nogo-A results in a hyperactive network. In addition, mGlu3 metabotropic glutamate receptors, which exhibit mutations in certain forms of schizophrenia, were downregulated specifically in the CA3 area. Furthermore, Nogo-A-/- mice showed disordered theta oscillations with decreased incidence and frequency, similar to those observed in mGlu3-/- mice. As disruptions in theta rhythmicity are associated with impaired spatial navigation, we tested mice using modified Morris water maze tasks. Mice lacking Nogo-A exhibited altered search strategies, displaying greater dependence on global as opposed to local reference frames. This link between Nogo-A and mGlu3 receptors may provide new insights into mechanisms underlying schizophrenia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057643PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0200896PLOS

Publication Analysis

Top Keywords

nogo-a
5
loss nogo-a
4
nogo-a encoded
4
schizophrenia
4
encoded schizophrenia
4
schizophrenia risk
4
risk gene
4
gene rtn4
4
rtn4 reduces
4
reduces mglu3
4

Similar Publications

Background: Spinal cord injury results in permanent neurological impairment and disability due to the absence of spontaneous regeneration. NG101, a recombinant human antibody, neutralises the neurite growth-inhibiting protein Nogo-A, promoting neural repair and motor recovery in animal models of spinal cord injury. We aimed to evaluate the efficacy of intrathecal NG101 on recovery in patients with acute cervical traumatic spinal cord injury.

View Article and Find Full Text PDF

Overexpression of Nogo-A changes nerve growth factor signaling dynamics in PC12 cells.

Cell Signal

December 2024

Research Service, Edward Hines Jr. Veterans Administration Hospital, Hines, IL, USA; Department of Molecular Pharmacology and Neuroscience, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.

The nerve growth factor (NGF) receptor TrkA is a tightly regulated receptor tyrosine kinase that activates neuronal signaling pathways promoting cell survival in addition to axonal and dendritic outgrowth. Previously, we showed that NGF and TrkA signaling is altered in neuron-like PC12 cells that overexpress Nogo-A, a protein known to influence axonal outgrowth and dendritic arborization associated with neuronal plasticity. In the present report, we provide evidence for changes in NGF-mediated receptor-level and downstream signaling that occur in cells overexpressing Nogo-A.

View Article and Find Full Text PDF

Validation of Peripheral Neuromodulation Mechanisms of Icariin in Knee Osteoarthritis-Related Chronic Pain.

J Cell Mol Med

December 2024

Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fuzhou, Fujian, China.

Knee osteoarthritis (KOA) is a chronic degenerative joint disease-causing chronic pain and disability. Neuromodulation of subchondral bone affects KOA-related pain and involves dorsal root ganglion (DRG). Our previous studies have demonstrated efficacy of icariin (ICA) in treating KOA, but neuromodulation mechanisms in peripheral nerves associated with the treatment of chronic pain in KOA remain unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Intrathecal drug administration is a promising method for delivering biologics to the central nervous system (CNS), but there is limited knowledge on how well intrathecally applied antibodies are tolerated and their pharmacokinetics.
  • This study involved administering a human monoclonal antibody against Nogo-A to non-human primates, assessing toxicity, pharmacokinetics, and pharmacodynamics with no observed side effects, indicating good tolerability.
  • Findings showed that the antibody was rapidly cleared from the cerebrospinal fluid but accumulated in the serum, effectively targeting Nogo-A in the CNS, which could enhance therapeutic strategies for CNS diseases.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!